Daiichi Sankyo Company, Limited (DSKYF)
OTCMKTS · Delayed Price · Currency is USD
23.55
+0.70 (3.06%)
At close: Jan 9, 2026
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 19,765 employees as of March 31, 2025. The number of employees increased by 1,039 or 5.55% compared to the previous year.
Employees
19,765
Change (1Y)
1,039
Growth (1Y)
5.55%
Revenue / Employee
$676,540
Profits / Employee
$95,691
Market Cap
41.48B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
| Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
| Mar 31, 2023 | 17,435 | 977 | 5.94% |
| Mar 31, 2022 | 16,458 | 425 | 2.65% |
| Mar 31, 2021 | 16,033 | 685 | 4.46% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| OpGen | 1 |
Daiichi Sankyo Company News
- 3 days ago - Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway - Business Wire
- 4 days ago - Daiichi Sankyo (DSKYF) Partners with GENESIS Pharma for VANFLYTA Distribution - GuruFocus
- 4 days ago - Daiichi Sankyo, GENESIS Pharma sign VANFLYTA deal in Central and Eastern Europe - Seeking Alpha
- 4 days ago - Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe - Business Wire
- 20 days ago - AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA's Breakthrough Therapy Designation In US - Nasdaq
- 20 days ago - ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer - Nasdaq
- 26 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript - Seeking Alpha
- 26 days ago - AstraZeneca : ENHERTU Combination Approved In US For 1st-Line HER2-Positive Metastatic Breast Cancer - Nasdaq